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Abstract
Preclinical studies are important in identifying the underlying mechanisms contributing to frailty. Frailty studies have mainly focused on male 
rodents with little directed at female rodents. Therefore, the purposes of this study were to identify the onset and prevalence of frailty across 
the life span in female mice, and to determine if frailty predicts mortality. Female C57BL/6 (n = 27) mice starting at 17 months of age were 
assessed across the life span using a frailty phenotype, which included body weight, walking speed, strength, endurance, and physical activity. 
The onset of frailty occurred at approximately 17 months (1/27 mice), with the prevalence of frailty increasing thereafter. At 17 months, 11.1% 
of the mice were pre-frail and by 26 months peaked at 36.9%. The percentage of frail mice progressively increased up to 66.7% at 32 months. 
Non-frail mice lived to 29 months whereas frail/pre-frail mice lived only to 26 months (p = .04). In closing, using a mouse frailty phenotype, 
we are able to identify that the prevalence of frailty in female mice increases across the life span and accurately predicts mortality. Together, 
this frailty phenotype has the potential to yield information about the underlying mechanisms contributing to frailty.
Keywords: Aging, Body weight, Mortality, Muscle, Physical function
Frailty is a complex phenotype seen in aging, which is associated 
with low physiologic reserves, decreased resilience, and resistance to 
stressors, causing vulnerability to adverse outcomes (1–4). Because 
the population of 60 year olds and older is expected to be 2 billion 
by 2050 and the prevalence of frailty increases with age, frailty will 
become an increasing challenge (5). Early identification of individ-
uals at risk of developing frailty, even at a pre-frail status, has the 
potential to make a significant impact on age-related disability, de-
pendence, and overall quality of life. Several lines of evidence attest 
that frailty can be prevented, or at least delayed, by the establishment 
of timely and appropriate interventions (6,7). Thus, intervening at 
the pre-frail stage by targeting key biological pathways may have 
important implications in either reversing pre-frailty or halting the 
subsequent development of frailty.
The investigation of frailty in preclinical models (naturally aging 
mice) using frailty assessment tools is an important step in the under-
standing of key biological pathways underlying the onset of frailty 
and increased prevalence of frailty across the life span. To foster 
translation of biological features of frailty, human frailty indexes 
and phenotypes have been reverse translated into mice (8–12). For 
instance, frailty is modeled as a clinical frailty index in mice by 
tracking the accumulation of age-specific deficits (9). The accumula-
tion of deficits increases with age similar to what occurs in humans 
(10). Frailty is also modeled as a frailty phenotype using perform-
ance measures such as grip strength, walking speed, endurance, and 
activity levels (8,11,13). This phenotype identifies non-frail, pre-frail, 
and frail mice similar to the human frailty phenotype established by 
Fried and colleagues (3).
Recently, the frailty assessment tools for mice (ie, mouse frailty 
index and phenotype) were revised by the original research groups. 
Whitehead and colleagues (14) modified several of the original 31 
measurements (9) because they were invasive and difficult to inte-
grate into a longitudinal, life span research study. The updated frailty 
index includes clinical observations of several biological systems (ie, 
musculoskeletal, integument, ocular, nasal systems, and respiratory) 
and signs of discomfort, body weight, and temperature. On the other 
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hand, the original mouse frailty phenotype (8) was recently modified 
with the inclusion of body weight and an established endurance test 
(ie, time to fatigue on a motorized treadmill) (12). Using this updated 
frailty phenotype, Baumann and colleagues (12) identified the onset 
and prevalence of frailty, and overall health and mortality risk in a 
cohort of male mice across the life span (14–37 months of age). The 
onset of frailty occurred at 17 months of age (100% survival rate) 
with the prevalence of frailty increasing across the life span; in that, 
nearly every mouse was frail by 32 months of age (52% survival 
rate). Because high body weight has potential to impact health status 
(12,15), the authors recommend heavy mice late in adulthood be 
considered positive for the frailty criterion of body weight.
Over the past 3 years, these mice frailty assessment tools have 
been successfully used by various research teams (11,13,16). The 
majority of the reported studies have used male mice with only a 
few studies investigating frailty in female mice. With this disparity in 
mind, in the current study we set out to determine the onset, preva-
lence, and mortality risk in female mice across the life span.
Methods
Animals and experimental design
Female C57BL/6 mice (n  =  29) were purchased from Jackson 
Laboratory (Bar Harbor, ME) at 5 months of age. Mice were sup-
plied with food and water ad libitum, housed under a 12-hour light 
to dark cycle at 20–23°C in specific pathogen-free facilities, and al-
lowed to age until death. Of the initial cohort, two mice were killed 
at 19 months of age due to non-age-related causes, leaving a total 
of 27 mice for this study. All animal procedures were in accordance 
with the standards set by the institutional animal care and use com-
mittees at the University of Minnesota and Boston University.
Testing was initiated at 17 months of age and continued every 
3 months (20, 23, . . . 32, or death) making this study a repeated 
measures research design, which allowed us to determine the life 
span of each individual mouse. On the basis of the National Institute 
of Aging, 17 months of age represents a 90% survival rate for female 
C57BL/6 mice and therefore any death prior to 17 months would 
be due to non-age-related conditions (malocclusion, hydrocephalus, 
or over-grooming). At every testing period (ie, 3-month interval), 
mice performed the assessments over a 1-week period (12). All pro-
cedures followed the same protocol for each testing period, and to 
ensure user reliability, all assessments were completed by the same 
investigators.
Body weight and body fat percentage
Body weights were obtained on an electronic scale (CS200; OHAUS, 
Parsippany, NJ), whereas body fat percentage was evaluated using 
a Lunar PIXImus densitometer (GE Lunar Corporation, Madison, 
WI). Briefly, a phantom mouse was first used as a calibration 
standard for quality control prior to each testing day. Mice were 
then anesthetized with isoflurane, placed on an adhesive specimen 
tray, and scanned with the skull excluded and tail included.
Walking speed
Walking speed was evaluated using a rotarod (Rota-Rod R/S; LSi 
Letica, Cornella, Spain). Others have also used the rotarod test to 
assess endurance, balance, and coordination (8,17,18). Mice were 
first warmed up on the rotarod by walking at 4 rpm for 30 seconds, 
at which point rotarod speed increased 1 rpm every 8 seconds up 
to 40 rpm over a 5-minute period. Time, in seconds, was recorded 
when the mouse was unable to sustain the rotation speed of the 
rotarod. Each mouse performed three trials with a 10-minute rest 
period in between each trial. The best score of these trials was used 
as walking speed.
Strength
Strength was evaluated using a grip meter test (P/N760483; 
Coulbourn Instruments, Whitehall, PA). Mice were lowered over the 
top of a wire grid so that the front and hind paws gripped the grid. 
The tail of each mouse was then pulled back while keeping the torso 
of the mouse in a horizontal position. When the mouse was unable 
to maintain its grip, the trial was over and strength, in grams, was 
recorded. Each mouse performed two trials with a 10-minute rest 
period in-between each trial. The best score of these trials was used 
as peak grip strength.
Endurance
Endurance was evaluated using a time to fatigue test on a motorized 
treadmill (Exer 3/6 Treadmill; Columbus Instruments, Columbus, 
OH). After a brief warm-up (5 m/min for 5 minutes), mice remained 
on the treadmill and time to fatigue began with speed increasing 1 m/
min every minute. Motivation was provided by tapping the mouse’s 
rear (19). Time to fatigue, in seconds, was recorded following the 
third time the mouse could no longer keep pace with the speed of the 
treadmill. Endurance was determined to be the total amount of time 
the mouse remained on the treadmill.
Physical activity
Physical activity was evaluated using the voluntary distance run on 
a running wheel (Model number: 80820F; Lafayette Instruments, 
Lafayette, IN). Mice were individually housed in wheel running 
cages for 4 days. The running distance, in revolutions, was recorded 
and converted to kilometer. The average distance ran per day (km/
day) was used to score physical activity.
Frailty criteria
The frailty phenotype used in this study was previously described 
in detail (12). Briefly, mice that fell in the bottom 20% for walking 
speed, strength, endurance, or physical activity, or in the top 20% for 
body weight were considered positive for frailty (ie, for that given 
criterion). These criteria were used to identify frailty cut-off values at 
20 months of age (Table 1). Mice with three or more positive frailty 
markers were identified as frail, mice with two positive markers 
were identified as pre-frail, and mice with one or no positive frailty 
marker were considered non-frail.
The age of 20 months was selected for three reasons. First, in our 
initial cohort (n  =  29) and that published by National Institute of 
Table 1. Frailty Criteria and Cut-off Values
Human Frailty  
Phenotype (3)
Mouse Frailty  
Phenotype  
(12)
Cut-off  
Values
Low activity Voluntary  
wheel running
Lower 20% (1.249 km/d)
Poor endurance Treadmill fatigue test Lower 20% (915.6 s)
Weakness Grip meter Lower 20% (239.1 g)
Slowness Rotarod test Lower 20% (27.6 s)
Lower body weight Body weight Upper 20% (44.1 g)
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Aging, this age represents >75% survival for female C57BL/6 mice, 
meaning it is near the maximal age before mice begin dying, making it 
an optimal age to predict frailty. In fact, from 20 to 26 months of age, 
approximately 30% of the mice in our cohort died. Second, 20 months 
for a mouse equate to approximately 60–70 human years (3,10), 
which correspond to the initial age bracket assessed by Fried and col-
leagues (3). Finally, because frailty is thought to be reversible, this age 
provides adequate time to implement possible life-changing interven-
tions. We have previously demonstrated that the same reasoning can 
be applied to male C57BL/6 mice at 23 months of age (12).
To determine if the frailty criteria outlined earlier accurately pre-
dict mortality, survival curves were constructed on mice identified as 
frail, pre-frail, and non-frail at 20 months of age. The cut-off values 
obtained at 20 months (Table 1) were then used to quantify the onset 
and prevalence of frailty for all other age groups (ie, 17–32 months).
Statistical analysis
A one-way repeated measures analysis of variance (mouse × time) was 
used to test age-related changes in body weight, body fat, walking 
speed, strength, endurance, and physical activity. In the event of a sig-
nificant analysis of variance, a Bonferroni correction was used. The re-
lationships between body weight and body fat percentage were fit with 
a simple linear regression and the square of the correlation coefficient 
(R2) was calculated. Differences between frail/pre-frail and non-frail 
were analyzed with an independent t test. A Kaplan–Meier test was 
used to assess life span characteristics and for comparison between 
groups (ie, frail, pre-frail, and non-frail). An α level of <.05 was used 
for all analyses. Values are presented as mean ± SEM. Statistical ana-
lyses were performed with Sigma Plot 14.0 (Systat Software Inc., Point 
Richmond, CA) or SPSS 24.0 (IBM Corp, Armonk, NY) software.
Results
Mouse mortality and identifying frail mice
The survival curve of the 27 female mice that completed the study is 
depicted in Supplementary Figure 1. The first and last mouse died at 
21.1 and 34.3 months, respectively, and the mean survival age was 
28.1 ± 0.6 months. In order to identify frail mice cut-off values for 
each frailty criterion (20th percentile), mice were rank ordered for 
each criterion from best to worst with the exception of body weight 
(Figure 1A). Mice were identified to have a positive marker of frailty 
if the mice performed below the cut-off values for walking speed 
(27.6 seconds), strength (239.1  g), endurance (915.6 seconds), or 
physical activity (1.249 km/d; Table 1). Mice were considered posi-
tive for the body weight frailty marker if they were 44.1 g or greater 
(Table 1). Using these criteria, we identified 17 mice as non-frail, 5 
mice as pre-frail, and 5 mice as frail at 20 months of age (Figure 1B).
Onset and prevalence of frailty
Cut-off values calculated at 20 months of age (Table 1, Figure 1A) 
were then used to determine the onset and prevalence of frailty for 
all other age brackets (Figure 2A). At 17 months of age, 11.1% of 
the mice were pre-frail, and by 26 months increased and peaked at 
36.9%. Following 26  months, this percentage declined to 18.2% 
at 29  months. The onset of frailty occurred at approximately 
17 months, and represented only 3.7% of the mouse cohort (1/27 
mice). The percentage of frail mice progressively increased to 66.7% 
at 32 months. In contrast, the percentage of non-frail mice steadily 
declined from 85.2% at 17 months to 18.2% at 29 months. Beyond 
29 months, no mice were identified as non-frail (Figure 2A).
Predicting mortality of frail mice
Mice identified as frail, pre-frail, and non-frail at 20 months were 
assessed using a Kaplan–Meier survival analysis to determine if our 
frailty criteria accurately predict mortality (Figure 2B). The five frail 
mice had a mean survival time of 26.9  ± 1.3  months and a 60% 
probability of dying before 27 months. Four of the five pre-frail mice 
died before 29 months (80% probability) and had a mean survival 
age of 26.5 ± 1.0 months. The mean survival age of the non-frail mice 
(n = 17) was 29.0 ± 0.8 months. Although not significantly different 
(p = .06), non-frail mice tended to live longer than frail and pre-frail 
Figure 1. Frailty status at 20 months of age. The mice were coded A–Z and 
AA (n = 27) and rank ordered by performance (A). The cut-off values of each 
criterion (body weight, walking speed, strength, endurance, and physical 
activity) are shown in A.  The gray-shaded areas identify the mice in the 
bottom 20% for performance and the top 20% for body weight. The summary 
of the criteria of number of frail markers for each mouse at 20 months of 
age (B). Frailty was defined if a mouse had three or more positive markers, 
whereas pre-frailty was designated if a mouse had two positive markers. 
Mouse B, H, N, V, and Z were identified as frail (black). Mouse D, M, Q, S, 
and W were identified as pre-frail (gray). The remaining mice (n = 17) were 
identified as non-frail (white).
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mice (Figure 2B). Therefore, we combined frail and pre-frail mice into 
one group and reanalyzed the data, and revealed that non-frail mice 
lived significantly longer than frail/pre-fail mice (p = .04) (Figure 2C).
Comparison between frail/pre-frail and non-frail 
mice early in life
To assess if the mice identified as frail or pre-frail at 20 months pre-
sented morphological and/or functional differences from the non-
frail mice earlier in life, the frail and pre-frail mice were again grouped 
together and compared to the non-frail mice at 17 and 20 months 
of age (Figure 3). Frail/pre-frail mice weighed 18%–21% more and 
possessed 23%–25% more body fat than the non-frail mice at 17 
and 20 months of age (p ≤ .01; Figure 3A and B). Walking speed 
was also different between frail/pre-frail and non-frail mice earlier 
in life, with time spent on the rotarod being 30% less at 17 months 
(p =  .05; Figure 3C). Endurance measured as treadmill time to fa-
tigue was 24% less in frail/pre-frail mice when compared to non-
frail mice at 20 months (p = .01; Figure 3D). Moreover, distance per 
day for voluntary wheel running was 56%–62% less in frail/pre-frail 
mice at 17 and 20 months of age (p ≤ .01; Figure 3E). In contrast 
to the robust difference in voluntary wheel running, strength deter-
mined by a grip test was only 10% less in frail/pre-frail mice when 
compared to non-frail mice at 20 months of age (p = .01; Figure 3F).
Age-related changes
Because of the longitudinal research design used in this study, it was 
possible to evaluate age-related changes in the same mice across 
several testing periods. For this analysis, a subset of 11 mice was 
assessed using a repeated measures analysis of variance across 
17–29 months of age, five consecutive testing periods.
Figure 3. Comparison between frail/pre-frail and non-frail mice early in life. 
Mice identified as frail/pre-frail (n = 10) and non-frail (n = 17) using the cut-off 
values determined at 20 months of age. An independent t test was performed 
to assess differences in body weight (A), % body fat (B), walking speed (C), 
endurance (D), physical activity (E), and strength (F) at 17 and 20 months of 
age. All values are expressed as mean ± standard error. * indicates p < .05 
comparing frail/pre-frail (black) to non-frail (white).
Figure 2. Frailty: onset, prevalence, and mortality. Prevalence of frailty using 
the cut-off values at 20 months of age was determined across the life span 
in female C57BL/6 mice (A). The onset of frailty was identified at 17 months 
of age (A). Kaplan–Meier survival curves for frail, pre-frail, and non-frail mice 
(B). Kaplan–Meier survival curves for frail/pre-frail and non-frail mice (C). * 
indicates p < .05 comparing frail/pre-frail (dark gray) to non-frail (black dot).
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Body weight and body fat percentage
Body weight increased 4%–11% at 20 and 23 months (p ≤ .04), 
and returned to baseline at 26 months before decreasing 20% at 
29 months (p = .05; Figure 4A). Body fat percentage also increased 
11% (not significant, p  =  .06 at 23  months) before decreasing 
20% at 29 months (p = .001; Figure 4B). Correlational analyses 
revealed that body weight and body fat percentage were related 
from 17 to 29  months of age (Supplementary Figure 2A–F), 
reaching a peak correlation of .89 (p < .001) at 29 months.
Functional characteristics
When compared to the initial baseline assessments performed at 
17  months, age-related changes were observed for all functional 
characteristics (Figure 4). Walking speed determined by time on the 
rotarod was the first variable to experience an age-related change, 
decreasing 48%–50% at 23–26 months of age (p ≤ .01; Figure 4C). 
Strength measured by a grip test was the next variable to exhibit 
an age-related change, decreasing 14%–21% at 26–29 months (p ≤ 
.04; Figure 4F). Endurance assessed by time to fatigue test decreased 
41% at 29 months (p < .03; Figure 4D). Physical activity determined 
by voluntary wheel running also experienced an age-related change 
at 29 months, decreasing 71% (p < .02; Figure 4E).
Discussion
In this study, we undertook a comprehensive approach to investigate 
a female cohort of mice across the life span and identified several 
important characteristics of frailty using a phenotype assessment 
tool. The frailty phenotype assessment tool included criteria of high 
body weight and impaired strength, walking speed, endurance, and 
physical activity. Using this approach, as previously demonstrated in 
male mice (12), it is possible to effectively characterize the onset and 
prevalence of frailty, and accurately predict mortality in female mice.
Frailty is a state of increased vulnerability to adverse health out-
comes, a higher risk of disability, hospitalizations, and mortality (1–4). 
Two clinical assessment tools, the frailty index and the frailty phenotype, 
are frequently used to identify frail individuals. The frailty index con-
ceptualizes frailty as a multidimensional clinical syndrome considering 
a wide array of outcome variables (10). It is defined as the number of 
deficits in an individual divided by the total number of deficits measured, 
and as such is an index of deficit accumulation. In contrast, the frailty 
phenotype denotes frailty functionally as represented by poor perform-
ance in three out of five criteria (ie, weight loss, exhaustion, weakness, 
slow walking speed, lack of activity) (3). These two clinical assessment 
tools were successfully reverse-translated for preclinical animal models 
with the overreaching goal to tease out the biological features associated 
with frailty status and diminished physical resilience (13,20).
Because frailty is prevalent in older women, the use of a female 
mouse model is relevant to age-related conditions that are pertinent 
to human frailty (21). To date, the number of studies investigating 
frailty in female mice has increased over the past 12 months. The 
majority of these studies used the frailty index score in various 
strains of mice (eg, 3xTg-AD, NIH Swiss, C57BL/6, CD-1) (22–25). 
The overall findings in most of the mouse strains indicate the frailty 
index score increases with age, suggesting that female mice experi-
ence age-associated health deficits (20,22,23).
In experimental aging research, the C57BL/6 is one of the most com-
monly used mouse strains (26). The C57BL/6 strain is popular because 
it has a well-defined short life span, the major physiological systems 
are well-documented, the cost is conservative, and there are similarities 
with human aging (27). In fact, initial studies with female C57BL/6 mice 
used a cross-sectional approach comparing various age groups (eg, 13 
vs 30 months; 5, 19, and 28 months) (9,14). Recent studies report as-
sessing frailty more than once in the same cohort of female C57BL/6 
mice over a duration of 5–6 months (20,24). Specifically, these studies 
began assessment of frailty when the mice were 16 or 17 months of 
age and ended the testing when mice were 21 or 23 months of age 
(20,24). Regardless of the approach, longitudinal or cross-sectional, the 
frailty index score increased in the female C57BL/6 mice. In contrast 
to the frailty index score, investigations in female C57BL/6 mice using 
the frailty phenotype are limited; yet, this assessment tool is valuable. 
The evaluation of frailty across the adult life span (mice from 17 to 
34.3 months of age, a duration of 17 months) in the same cohort of 
mice has the potential to yield significant information about the pro-
gression of frailty.
Here, we demonstrate that the prevalence of frailty in female 
C57BL/6 mice increased across the life span. Indeed, the prevalence 
of frailty (frail/pre-frail) increased from 42% to 72% between 23 
and 26 months of age, when the survival rate was greater than 50%. 
An increased prevalence of frailty has recently been reported in fe-
male NIH Swiss mice using a modified accumulation deficit model 
(29 measures) (23). These studies validate that assessment tools for 
frailty accurately depict an increase in the prevalence of frailty across 
the life span in mice. Moreover, our data provide clarity to a pre-
vious report showing inconclusive results; in that, the prevalence of 
frailty did not increase when using the Valencia Score frailty pheno-
type (16). Collectively, these results are consistent with that seen in 
humans, where the prevalence of frailty in females increased from 
3% to 11% at 65–75 years old to 60% at 80 years old (3).
Figure 4. Age-related changes for each criterion. Eleven mice were used to 
determine age-related changes in body weight (A), % body fat (B), walking 
speed (C), endurance (D), physical activity (E), and strength (F) using one-way 
repeated measures analysis of variance followed by Bonferroni post hoc. All 
values are expressed as mean ± standard error. * indicates p < .05 comparing 
to 17 months of age.
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Another important characteristic of frailty is the time point within 
the life span at which frailty is first initiated (ie, onset of frailty). The 
significance of recognizing the onset of frailty lies in its potential to 
discover the biological mechanisms associated with the pre-frail status 
and to initiate timely interventions to prevent frailty. In this study, we 
estimate that the onset of frailty occurred approximately at 17 months 
of age. However, because we did not measure any time or age prior to 
17 months, it is possible the onset of frailty may have occurred earlier 
in life. We suspect this is not the case as only 3.7% of our mouse cohort 
was considered frail at 17 months of age, which corresponds to 1 out 
of 27 mice, meaning at the most only 1 mouse was frail prior to this 
point. The difficulty in defining the precise year when frailty emerges in 
humans was reported recently in a study that examined the data from 
the Longitudinal Aging Study Amsterdam and the InCHIANTI Study 
(28). In order to capture the onset of frailty in both humans and in 
preclinical models, the research design must overcome this challenge.
Moreover, we were able to successfully predict that non-frail mice 
(29.0 months) live longer than frail/pre-frail mice (26.7 months). In 
fact, in close examination over a 6-month period (20–26 months of 
age), 44% of the frail/pre-frail mice died compared to only 12% 
of the non-frail mice. However, in order to identify mortality risk, 
it was necessary to combine pre-frail and frail mice at 20 months 
of age into one experimental group. Although we do not know the 
underlying mechanisms of why we cannot distinguish between frail 
and pre-frail female at this time point, our data still support that 
frail/pre-frail mice have impaired health and die earlier than non-
frail mice. These findings suggest that a decline in specific physical 
activities such as walking speed, strength, activity level, and endur-
ance can provide information about the underlying health status 
in mice.
Recently, there has been an increased awareness on the 
topics of resilience, frailty, and aging in both mice and humans. 
Resilience is defined as the ability of an organism to respond to 
stress (29,30). It is likely that frailty and resilience are closely re-
lated. The mouse frailty phenotype used in this study measured 
body weight, strength, and activity level, all measures that did 
not stress the mouse. In addition, time to fatigue (endurance) and 
walking speed were also analyzed, two assessments that evaluated 
the mouse’s ability to respond to added physical stresses, or stress 
that acutely disrupts normal physiological functions. With this in 
mind, the data suggest female mice with increased resilience have 
the potential to live longer. In contrast, female mice that performed 
poorly during the time to fatigue and walking speed tests early in 
life (frail/pre-frail status) exhibited signs of reduced resilience and 
typically died earlier in life. It is possible that reduced resiliency 
may play a causative role in the development of the frail/pre-frail 
status. Importantly, we suggest that the mouse frailty phenotype 
has the potential to test resiliency in adulthood and be an approach 
to test frailty interventions.
The underlying mechanisms contributing to the onset, increased 
prevalence of frailty across the life span, and risk of mortality in fe-
male mice are likely multifactorial. Currently, there are several pro-
posed mechanisms such as low-grade inflammation, oxidative stress, 
cellular senescence, and DNA damage (31–33). This scenario is fur-
ther complicated in aging females as they go through ovarian sen-
escence, in which levels of estrogen decline (34–38). Estrogen status 
has been reported to influence many morphological and physio-
logical measures (34,39–42). For instance, loss of estrogen (via 
ovariectomy) increases body weight and body fat percentage while 
reducing cage activities, voluntary wheel running distance, and skel-
etal muscle contractile function in female rodents (34,41,42). These 
observations are similar to those seen as women transition through 
menopause (43–45). Therefore, we suggest that an important factor 
contributing to frailty in females is estrogen status. Our data support 
this concept because around the time of ovarian senescence (~16–
20  months of age in C57BL/6) (34,35), mice begin to experience 
an increase in body weight and a progressive reduction in overall 
function. Moreover, at this time we also observed that frail/pre-frail 
mice were different than non-frail mice, in particular when it came 
to body weight, body fat percentage, and voluntary wheel running 
distance. Although we cannot directly link estrogen status to our 
frailty phenotype, future studies should consider using a longitu-
dinal life span design to determine how hormones, frailty (functional 
measures) status, and resilience interact.
In summary, here we show that the frailty phenotype is a useful 
assessment tool. This frailty phenotype is accurate in identifying the 
onset of frailty, the increasing prevalence of frailty, and the mor-
tality risk across the life span of C57BL/6 female mice. Because the 
frailty phenotype is a well-validated tool, it may be beneficial in 
identifying mechanisms contributing to frailty and reduced resili-
ence with age.
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